Research Article
A Multicentre Randomized Clinical Trial on Efficacy and Safety of Huxin Formula in Patients Undergoing Percutaneous Coronary Intervention
Table 2
Baseline clinical data (
, %).
| | Control group () | Treatment group () | |
| Age () | | | 0.09 | Gender | | | | Male | 249 (78.8) | 250 (77.2) | 0.62 | Female | 67 (21.2) | 74 (22.8) | Height () | | | 0.60 | Weight () | | | 0.02 | Pulse () | | | 0.31 | Breath () | | | 0.46 | Heart rate () | | | 0.28 | SBP () | | | 0.49 | DBP () | | | 0.47 | Combined disease | | | | Dyslipidemia | 96 (30.4) | 91 (28.1) | 0.52 | Hypertension | 182 (57.6) | 179 (55.2) | 0.55 | Diabetes | 72 (22.8) | 60 (18.5) | 0.18 | Stroke | 16 (5.1) | 13 (4.0) | 0.52 | Heart failure | 10 (3.2) | 12 (3.7) | 0.71 | Gastrointestinal disorder
| 31 (9.8) | 26 (8.0) | 0.43 | Arrhythmia | 18 (5.7) | 18 (5.6) | 0.94 | Medical history | | | | Smoking | 159 (50.3) | 165 (50.9) | 0.88 | Drinking | 50 (15.8) | 52 (16.0) | 0.94 | Family history of CVD | 41 (13.0) | 49 (15.1) | 0.43 | Allergy | 31 (9.8) | 30 (9.3) | 0.81 | Clinical classification of CHD | | | | Unstable angina | 168 (53.2) | 193 (59.6) | 0.10 | Ml | 148 (46.8) | 131 (40.4) | Cardiac functions | | | | I | 117 (37.0) | 122 (37.7) | | II | 157 (49.7) | 166 (51.2) | 0.70 | III | 42 (13.3) | 36 (11.1) | |
|
|
CHD: coronary heart disease, CVD: cardiovascular disease, DBP: diastolic blood pressure, MI: myocardial infarction, and SBP: systolic blood pressure.
|